NCT02921490

Brief Summary

Chronic pain incurs over half a trillion dollars in lost productivity (healthcare, lost wages, etc) annually. The most common source is low back pain (LBP), often from facet joints. The clinical evaluation of facet joints is challenging and anatomic imaging findings of facet joint; degenerative change; correlate poorly with pain. Therefore, it is difficult to select appropriate candidate patients/facet joints to treat. Misguided percutaneous treatment can cost thousands of dollars per session and delay diagnoses. Very limited retrospective information suggests that high grade peri-facet MRI signal change correlates to the side of LBP. However, this has not fully characterized the imaging findings and has not correlated to expert clinical exam/percutaneous response, precluding robust and meaningful clinical impact. Minimal retrospective data concludes inflammatory changes can be identified on FDG-PET exams, but the evidence of correlation to patient pain is lacking. Limited DWI exists for inflammatory spondyloarthropathies and myopathies, but is also lacking. This is an exploratory study investigating the utility of FDG PET activity and MRI signal change around facet joints in the clinical management of low back pain. This study will help determine if such imaging biomarkers could change clinical management. Additionally, this will provide data that will be vital to planning a larger prospective study evaluating the ability of imaging biomarkers to predict response to comparison medial branch blocks and RF ablation for treatment of facet joint pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable low-back-pain

Timeline
Completed

Started Sep 2016

Longer than P75 for not_applicable low-back-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

September 29, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 3, 2016

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2019

Completed
5 months until next milestone

Results Posted

Study results publicly available

February 19, 2020

Completed
Last Updated

February 19, 2020

Status Verified

February 1, 2020

Enrollment Period

2.2 years

First QC Date

September 29, 2016

Results QC Date

January 20, 2020

Last Update Submit

February 7, 2020

Conditions

Outcome Measures

Primary Outcomes (8)

  • Facet Joint High Grade FDG Activity Concordance to Pain

    Concordance of high grade FDG scores with clinical impression

    2 years

  • Facet Joint All Grades of FDG Activity Concordance to Pain

    Number/percentage of subjects (reported in sides, with two sides (Left or Right) per patient) for whom any grade (any evidence of increased FDG activity) of FDG scores are in concordance with clinical impression

    2 years

  • Facet Joint High Grade MRI Signal Change Concordance to Pain

    Number/percentage of subjects (reported in sides, with two sides (Left or Right) per patient) for whom any grade (any evidence of increased FDG activity) of FDG scores are in concordance with clinical impression

    2 years

  • Facet Joint Any Grade of MRI Signal Change Concordance to Pain

    Number/percentage of subjects (reported in sides, with two sides (Left or Right) per patient) for whom any grade (any evidence of increased FDG activity) of FDG scores are in concordance with clinical impression

    2 years

  • Facet Joint High Grade FDG Activity Potential Effect on Management

    Number/percentage of subjects for whom high grade FDG scores would change clinical management

    2 years

  • Facet Joint All Grades of FDG Activity Potential Effect on Management

    Number/percentage of subjects for whom any grade FDG scores would change clinical management

    2 years

  • Facet Joint High Grade MRI Signal Change Potential Effect on Management

    Number/percentage of subjects for whom high grade MRI facet joint signal change would change clinical management

    2 years

  • Facet Joint Any Grade MRI Signal Change Potential Effect on Management

    Number/percentage of subjects for whom any grade MRI facet joint signal change would change clinical management

    2 years

Study Arms (1)

PET/MR recipients

EXPERIMENTAL

All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.

Device: FDG PET/MR examination.

Interventions

All recruited patients will undergo an FDG PET examination focused on the lumbar spine.

PET/MR recipients

Eligibility Criteria

Age50 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female patients over the age of 50-100 years with clinically suspected facetogenic low back pain.
  • Patients must be considered to have at least a 60% chance of having facet joints as the major source of low back pain based on overall clinical impression.
  • All patients will undergo a standardized clinical exam by an experienced physical medicine and rehabilitation clinician to confirm clinical suspicion of axial low back pain.
  • Patients with either unilateral or bilateral axial low back pain may be enrolled.

You may not qualify if:

  • Pregnancy
  • Prior lumbar back surgery
  • History of endovascular repair of abdominal aortic aneurysm or other postoperative change likely to introduce imaging artifact to the lumbar spine
  • Suspected spine infection
  • Known osseous metastatic or other osseous malignancy
  • Facet joint percutaneous treatment within the past 2 months
  • History of major lumbar spine trauma
  • Inability to provide own consent
  • Claustrophobia, cardiac pacemaker/wires in place, any absolute contraindication to MRI
  • Impaired renal function indicated by a GFR less than 30
  • Gadolinium allergy
  • Highly radiosensitive medical conditions
  • Patients who are unable to lay quietly for 60 minutes of imaging

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

MeSH Terms

Conditions

Low Back Pain

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Vance Lehman
Organization
Mayo Clinic

Study Officials

  • Vance T Lehman

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D. , Assistant Professor of Radiology

Study Record Dates

First Submitted

September 29, 2016

First Posted

October 3, 2016

Study Start

September 1, 2016

Primary Completion

November 1, 2018

Study Completion

October 1, 2019

Last Updated

February 19, 2020

Results First Posted

February 19, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations